The primary goal of the study is to collect standardized patient and clinician reported outcome measures for patients diagnosed with a range of dermatological conditions in an academic clinical practice setting. By regularly measuring outcomes longitudinally in patients treated in a real-world setting, this study will provide valuable and necessary information as to the impact of both the disease and its treatments on patients over time and will inform the optimal clinical management of patients with living with dermatological disease.
The study is a multi-center, longitudinal, observational study to describe longitudinal trajectories of Clinician-Reported Outcomes (ClinROs) and Patient-Reported Outcomes (PROs) in patients with select dermatological conditions. This study will collect data using validated clinical instruments and patient-reported data on the disease course of alopecia areata (AA), atopic dermatitis (AD), hidradenitis suppurativa (HS), psoriasis (PsO), and vitiligo (VL), including symptom assessments and quality of life (QoL) measures from a patient perspective, to supplement routine clinical data collected from their healthcare providers. ClinRO data will be collected at baseline and routine follow-up visits for up to two years. PRO data will be collected directly from patients at baseline and at pre-specified follow-up time points (as defined in Tables 1 - 2e) for up to two years. The objectives of this study are: * To describe longitudinal changes in disease activity, symptom control and both physical and mental HrQoL based on both ClinROs and PROs * To identify patient, disease and treatment factors associated with changes in PROs over time * To describe the association between PROs, ClinROs and clinical outcomes
Study Type
OBSERVATIONAL
Enrollment
10,000
As this is an observational study, there are no interventions assigned to either cohort.
OM1
Boston, Massachusetts, United States
Overall body surface area involvement (%BSA-AD, single score, scored 0-100)
A simple measure of percent body surface area involved that complements the IGA in providing a relatively quick accurate representation of disease extent and severity.
Time frame: Baseline to 2 years
Investigator Global Assessment (IGA, scored 0-4; clear, almost clear, mild, moderate, and severe).
A 5-point IGA scale including morphologic descriptions, ranging from 0 (clear) to 4 (severe).
Time frame: Baseline to 2 years
Dermatology Life Quality Index (DLQI, 10 items, scored 0-30)
The DLQI consists of 10 questions concerning patients' perception of the impact of skin diseases on different aspects of their health-related quality of life over the last week
Time frame: Baseline to 2 years
Work Productivity and Activity Impairment questionnaire (WPAI,-GH v2.0, 6 items)
The questionnaire has four domains: Work Time Missed; Percent Impairment While Working; Percent Overall Work Impairment; and Percent Activity Impairment. Only one domain (Percent Activity Impairment) is completed by patients who are not currently employed
Time frame: Baseline to 2 years
EuroQoL 5-dimension (EQ-5D; 5 items and a single VAS)
EQ-5D is an instrument which evaluates the generic quality of life developed in Europe and widely used. The EQ-5D descriptive system is a preference-based HRQL measure with one question for each of the five dimensions that include mobility, self-care, usual activities, pain/discomfort, and anxiety/depression
Time frame: Baseline to 2 years
Patient Health Questionnaire-2 (PHQ-2, 2 items)
A simple two-item questionnaire evaluating the degree to which an individual has experienced depressed mood and anhedonia over the past two weeks. This survey is intended to screen for potential depression and is not diagnostic
Time frame: Baseline to 2 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.